Literature for peptidase M28.010: glutamate carboxypeptidase II

(References are filtered for relevance to Review. To remove the filter click here. See explanation.)

2024
1. Hoxie,N., Qiu,Y., Kales,S.C., Schneider,R., Hu,X., Dalal,A., Ford-Scheimer,S.L., Wiseman,R., Tsukamoto,T., Wei,H., Slusher,B.S., Janiszewski,J.S. and Hall,M.D.
   Development of a high-throughput dual-stream liquid chromatography-tandem mass spectrometry method to screen for inhibitors of glutamate carboxypeptidase II
   Rapid Commun Mass Spectrome9772-e9772. PubMed  Europe PubMed DOI  V
2. Ismuha,R.R., Ritawidya,R., Daruwati,I. and Muchtaridi,M.
   Future Prospect of Low-Molecular-Weight Prostate-Specific Membrane Antigen Radioisotopes Labeled as Theranostic Agents for Metastatic Castration-Resistant Prostate Cancer
   Molecules29, PubMed  Europe PubMed DOI  V
3. Jiang,Z., Kadeerhan,G., Zhang,J., Guo,W., Guo,H. and Wang,D.
   Advances in prostate-specific membrane antigen-targeted theranostics: from radionuclides to near-infrared fluorescence technology
   Front Immunol15, 1533532-1533532. PubMed  Europe PubMed DOI  V
4. Maes,J., Gesquiere,S., De Spiegeleer,A., Maes,A. and Van de Wiele,C.
   Prostate-Specific Membrane Antigen Biology and Pathophysiology in Prostate Carcinoma, an Update: Potential Implications for Targeted Imaging and Therapy
   Int J Mol Sci25, PubMed  Europe PubMed DOI  V
5. Peters,D.E.
   Targeting glutamate carboxypeptidase II in IBD
   Adv Pharmacol101, 265-285. PubMed  Europe PubMed DOI  V
2023
6. Strauss,A.S., Bolenz,C., Beer,A.J., Zengerling,F., Beer,M. and Miksch,J.
   [Opportunities for prostate-specific membrane antigen hybrid imaging in prostate cancer]
   Urologie62, 1153-1159. PubMed  Europe PubMed DOI  V
2022
7. Hawkey,N.M., Sartor,A.O., Morris,M.J. and Armstrong,A.J.
   Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches
   Clin Adv Hematol Oncol20, 227-238. PubMed  Europe PubMed  V
8. Jia,A.Y., Kashani,R., Zaorsky,N.G., Baumann,B.C., Michalski,J., Zoberi,J.E., Kiess,A.P. and Spratt,D.E.
   Lutetium-177 Prostate-Specific Membrane Antigen Therapy: A Practical Review
   Pract Radiat Oncol12, 294-299. PubMed  Europe PubMed DOI  V
2016
9. Evans,J.C., Malhotra,M., Cryan,J.F. and O'Driscoll,C.M.
   The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease
   Br J Pharmacol173, 3041-3079. PubMed  Europe PubMed DOI  V
10. Vornov,J.J., Hollinger,K.R., Jackson,P.F., Wozniak,K.M., Farah,M.H., Majer,P., Rais,R. and Slusher,B.S.
    Still NAAG'ing after all these years: the continuing pursuit of GCPII inhibitors
    Adv Pharmacol76, 215-255. PubMed  Europe PubMed DOI  V  I
2012
11. Barinka,C., Rojas,C., Slusher,B. and Pomper,M.
    Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer
    Curr Med Chem19, 856-870. PubMed  Europe PubMed DOI  V  I
12. Ferraris,D.V., Shukla,K. and Tsukamoto,T.
    Structure-activity relationships of glutamate carboxypeptidase II (GCPII) inhibitors
    Curr Med Chem19, 1282-1294. PubMed  Europe PubMed DOI  V  I
2008
13. Baslow,M.H.
    The astrocyte surface NAAG receptor and NAAG peptidase signaling complex as a therapeutic target
    Drug News Perspect21, 251-257. PubMed  Europe PubMed DOI  V  T
2007
14. Tsukamoto,T., Wozniak,K.M. and Slusher,B.S.
    Progress in the discovery and development of glutamate carboxypeptidase II inhibitors
    Drug Discov Today12, 767-776. PubMed  Europe PubMed DOI  V  I
2006
15. [YEAR:10-6-2006]Schneider,E. and Ryan,T.J.
    Gamma-glutamyl hydrolase and drug resistance
    Clin Chim Acta374, 25-32. PubMed  Europe PubMed DOI  V
2005
16. [YEAR:28-7-2005]Neale,J.H., Olszewski,R.T., Gehl,L.M., Wroblewska,B. and Bzdega,T.
    The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia
    Trends Pharmacol Sci26, 477-484. PubMed  Europe PubMed DOI  V
2004
17. Carter,R.E. and Coyle,J.T.
    Glutamate carboxypeptidase II
    [ISSN:0-12-079610-4]2, 960-963.  V
2001
18. Jackson,P.F. and Slusher,B.S.
    Design of NAALADase inhibitors: a novel neuroprotective strategy
    Curr Med Chem8, 949-957. PubMed  Europe PubMed  V  I